Converting immune inhibitory signal into immune stimulatory signal
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
cancer immunotherapy (tumor microenvironment)
Modality
Monoclonal Antibody
Mechanism
immune checkpoint signal converter (inhibitory-to-stimulatory antibody)
Target
—
rNPV Envelope
Low
-$42.9M
costs +25% · peak −25%
Base
-$33.0M
cumulative PoS 1.5%
High
-$23.1M
costs −25% · peak +25%
This is an illustrative oncology-biologic/platform envelope for cohort consistency only. Costs reflect biologic-nanoparticle CMC plus checkpoint-combination trial complexity; PoS is held below standard mAb baselines because the asset is a preclinical platform with target=None and no defined lead indication or clinical candidate.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.70
Modality fit · 30%
0.51
Whitespace · 30%
0.50
Composite 0.584 — composite-score rank #34 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#22) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
Immunoswitch nanoparticle platform (Kosmides/Sidhom/Schneck)
The direct asset archetype: nanoparticles co-displaying anti-PD-L1 and anti-4-1BB antibodies to link tumor cells and CD8 T cells and convert inhibitory checkpoint context into costimulation.
Criteria 1: exact mechanism and platform; used as the product-reality anchor rather than treating the invention as a defined antibody.
Nivolumab-based checkpoint blockade
Clinical standard for PD-1 pathway blockade and the therapeutic class whose limitations the immunoswitch tries to address. It is a pathway comparator, not a same-product comparator.
Criteria 2 and 4: launched checkpoint antibody class anchor; not sufficient to justify a novel-mAb DCF for a nanoparticle platform.
4-1BB agonist antibody class
Adjacent costimulatory pathway precedent. The class supports biological plausibility but also highlights systemic immune-toxicity concerns that local nanoparticle presentation is meant to mitigate.
Criteria 1 and 4: same pathway component, different delivery format; retained as an adjacent cautionary anchor.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $12.0M | 24 mo | 34.0% | [0] [1] |
| Phase I | $45.0M | 18 mo | 56.0% | [1] [2] |
| Phase II | $120.0M | 30 mo | 22.0% | [1] [2] [3] |
| Phase III | $260.0M | 42 mo | 42.0% | [2] [3] |
| NDA/BLA Review | $15.0M | 12 mo | 84.0% | [2] |
Multiplier handling: Eligible multipliers (combination_immunotherapy_rationale) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$250.0M peak · WACC 15.0%
Peak revenue. For an enabling nanoparticle platform, full product peak revenue is not the right academic value capture metric. The $250M figure is a conservative illustrative product-equivalent peak for pipeline consistency, standing in for a licensed or partnered solid-tumor immunotherapy niche rather than a platform-wide revenue claim.
WACC. Preclinical immuno-oncology platform risk, target ambiguity, and combination-toxicity questions justify a high discount rate.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$33.0M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$135.7M
P25
-$39.8M
P50 (median)
-$13.3M
P75
-$7.7M
P95
-$4.2M
Prob ≥ 0
0.7%
Evidence register
3 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
JHU asset is an immunoswitch nanoparticle platform, not a defined antibody target cmo_findings.asset_class_reality | Immunoswitch Particles for the Conversion of Inhibitory Signals to Co-stimulatory Signals regulatory | 2017-03-17 | high |
Peer-reviewed immunoswitch proof of concept stage_profile.preclinical.pos | Dual Targeting Nanoparticle Stimulates the Immune System to Inhibit Tumor Growth peer_review | 2017-06-27 | high |
Checkpoint blockade is the pathway anchor comparators[1] | Nivolumab drug information regulatory | 2025-01-01 | high |
Thesis
Why this asset earns its rank
This is not a defined mAb candidate; it is an enabling immuno-oncology delivery platform. The JHU asset is an immunoswitch nanoparticle that co-presents anti-PD-L1 and anti-4-1BB antibodies to physically link tumor cells and CD8 T cells, suppressing an inhibitory checkpoint signal while supplying costimulation. The rNPV envelope is shown only for cohort consistency - the rNPV is not the decision criterion here, which is why the asset is classified partnership_candidate rather than vc_fundable.
The comparator frame is checkpoint biology plus nanoparticle delivery, not a novel-antibody DCF. Nivolumab validates the PD-1 pathway, while the immunoswitch paper validates the local co-presentation concept in melanoma and colon mouse models. The engine result is -$42.9M to -$23.1M, with a base rNPV of -$33.0M and cumulative PoS of 1.5%; that should be interpreted as a conservative license-or-partner envelope for one eventual lead program, not the value of every possible immunoswitch application.
Verdict: credible platform science with a commercial path only after a lead indication, manufacturable construct, and translational safety package are defined. It earns its rubric rank through immuno-oncology relevance and mAb-like pathway biology, but a CMO would not diligence it as a target-defined antibody yet.
Key risks
Asset-specific, not generic biotech risks
- Asset-class mismatch: target=None is appropriate because the invention is a nanoparticle platform, not a single antibody target or candidate.
- Translation risk: murine melanoma/colon activity may not predict human T-cell exhaustion biology or solid-tumor penetration.
- Toxicity risk: 4-1BB agonism can create systemic immune toxicity; the platform must prove local presentation avoids that liability.
- CMC risk: dual-antibody nanoparticle consistency, conjugation density, and release specifications will be gating before any IND.